pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Entyvio
drug · antibody
save

vedolizumab

Phase 3updated 6mo ago
by $TAK TAKEDA PHARMACEUTICAL CO LTD🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 1
  • tagApproval88 co-mentions · 22 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for ulcerative colitis and crohn's disease and 8 investigational indications.

indications

indications
IBD (Crohn's + UC)

targets

Integrin alpha-4/beta-7

all catalysts(0)

nothing on the calendar yet

Trials studying vedolizumab

  • phase4A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Settingrecruitingn=200
  • —VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Studyactive not recruitingn=300
  • phase4A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)recruitingn=65
  • phase3A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumabactive not recruitingn=573
  • phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Diseaserecruitingn=100
  • phase2Vedolizumab for the Treatment of Collagenous Gastritisactive not recruitingn=11
  • phase3A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Diseaserecruitingn=70
  • phase3A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)recruitingn=240

News(10)

  • Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
    Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolsteri…
    biospace · 27d ago
  • Gilead’s pill posts stronger colitis remission rates than Entyvio
    Gilead Sciences will start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year after data from a Phase 2 dose-finding trial suggested that the drug looked better than rival…
    endpoints · 28d ago
  • Lilly, Foghorn part ways; Wave’s FDA-approved plans
    The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
    biopharma_dive · 1mo ago
  • Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
    Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.
    fiercebiotech · 2mo ago
  • Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
    Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.
    fiercebiotech · 2mo ago
  • Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
    Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
    fiercebiotech · 2mo ago
  • 5 NextGen winners who went public this year (and which ones are hiring)
    BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.
    biospace · 3mo ago
  • Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
    Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…
    fiercebiotech · 3mo ago
  • Abivax shares surge as worries subside over immune drug’s cancer risk
    According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
    biopharma_dive · 4mo ago
  • cAMPfield lands $180M to build gut disease drug
    The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
    biopharma_dive · 5mo ago
view all news mentions →
brand
Entyvio
trade names
Entyvio
generic
vedolizumab
MOA
Integrin alpha-4/beta-7 inhibitor
indication
Crohn's Disease (Regional Enteritis)
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?